Figure 2.
The effect of EGF and PDGF‐BB inhibition on Ang II‐induced phenotypic transformation of VSMCs. A, Effect of EGF inhibitor Gefitinib (ZD1839) on phenotypic transformation markers for phenotypic transformation of VSMCs. B, Effect of PDGF‐BB inhibitor Sunitinib Malate on phenotypic transformation markers in phenotypic transformation of VSMCs. Gefitinib (1 µmol/L) and Sunitinib Malate (2 µmol/L) were added 24 h before Ang II (10−5 mmol/L) treatment of VSMCs. Total protein was extracted 48 h later. The expressions of α‐SM‐actin, Calponin, SM22a and OPN at the protein level were analysed by Western blotting analysis. (Data were expressed as X ± S, n = 3; * P < .05 vs control group, Suntinib group and Gefitinib group; # P < .05 vs the Ang II group)